Abstract
Heart transplantation is a successful treatment for end-stage heart failure with international 1-year and 5-year survival rates of 81 % and 69 % and a median survival after the first year of 14 years. Assessment, transplantation, follow-up, and complications of recipients are managed by a multiprofessional multidisciplinary team which must include the pathologist. His/her role includes confirming the diagnosis in the recipient’s heart either at the time of assessment on endomyocardial biopsy or after surgery by examination of the explanted heart. Biopsy diagnosis of acute cellular and antibody-mediated rejection should be done using the Working Formulations of the International Society for Heart and Lung Transplantation. Chronic rejection/cardiac allograft vasculopathy involves the coronary arteries and is diagnosed using imaging modalities. A role for standardized biopsy diagnosis of allograft microvasculopathy has yet to be agreed. Other complications such as malignancy, infections, and other side effects of drug therapy often require access to pathology and other laboratory services. Provision of a pathology service must include rapid biopsy diagnosis and access to immunohistochemistry, cytopathology, molecular genetics, and autopsy laboratory services, all working to approved national laboratory standards. Contributing to collaborative ethically approved research using pathological tissue, retained with appropriate consent, is an important part of the pathologist’s role. The pathologist must also ensure they maintain a consistently high standard of diagnostic practice through participation in regular audit and reproducibility studies, on-going education in newer aspects of transplant medicine and immunology through specialist societies and journals, and networking with transplant pathologists in other centers. Digital resources may be of help in this regard. This chapter outlines the major areas of practice in which pathologists can contribute to the multidisciplinary care of the transplant recipient.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147–62.
Billingham ME. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy. J Heart Transplant. 1990;9(3 Pt 2):272–6.
Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990;9(6):587–93.
Castellani C, Angelini A, de Boer OJ, van der Loos CM, Fedrigo M, Frigo AC, et al. Intraplaque hemorrhage in cardiac allograft vasculopathy. Am J Transplant. 2014;14(1):184–92.
Caves PK, Stinson EB, Billingham ME, Shumway NE. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet. 1974;1(7862):821–6.
Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6(1):150–60.
Hiemann NE, Wellnhofer E, Knosalla C, Lehmkuhl HB, Stein J, Hetzer R, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation. 2007;116(11):1274–82.
John R, Rajasinghe HA, Chen JM, Weinberg AD, Sinha P, Mancini DM, et al. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg. 2001;72(2):440–9.
Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327–40.
Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245–74.
Loupy A, Toquet C, Rouvier P, Beuscart T, Bories MC, Varnous S et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection. Am J Transplant. 2016:16(1):111–20.
Luk A, Metawee M, Ahn E, Gustafsson F, Ross H, Butany J. Do clinical diagnoses correlate with pathological diagnoses in cardiac transplant patients? The importance of endomyocardial biopsy. Can J Cardiol. 2009;25(2):e48–54.
Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report – 2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):996–1008.
Mehra MR, Kobashigawa JA, Deng MC, Fang KC, Klingler TM, Lal PG, et al. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant. 2008;27(3):297–301.
Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717–27.
Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–20.
Vecchiati A, Tellatin S, Angelini A, Iliceto S, Tona F. Coronary microvasculopathy in heart transplantation: consequences and therapeutic implications. World J Transplant. 2014;4(2):93–101.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Burke, M., Potena, L. (2016). Cardiac Transplantation and the Contribution of Pathology. In: Leone, O., Angelini, A., Bruneval, P., Potena, L. (eds) The Pathology of Cardiac Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-46386-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-46386-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46384-1
Online ISBN: 978-3-319-46386-5
eBook Packages: MedicineMedicine (R0)